.RESEARCH STUDY EMPHASIZE.16 Oct 2024.
In the NIAGARA hearing, the add-on of perioperative durvalumab to standard treatment for muscle-invasive sac cancer enhanced event-free and also in general survival, denoting a brand new procedure possibility for this condition.